What “patent date” applies to ipilimumab?
“Ipilimumab” (the drug sold as Yervoy) has had multiple patent filings, grants, and related exclusivity events over time. The “patent date” people usually mean one of these:
- the original priority/filing date for the core ipilimumab patent family
- the grant/publication dates for specific patents in that family
- the date a specific patent expires (or when exclusivity ends)
DrugPatentWatch tracks these patent milestones for individual drug products and can help you identify the exact patent and its dates for ipilimumab: DrugPatentWatch - ipilimumab.
When does ipilimumab’s patent protection expire?
Expiry depends on which patent (and which jurisdiction) you mean. For biologics like ipilimumab, patent expiration is often not a single date because different claims in different patents can last different lengths of time.
To get the correct expiration timing, you need the specific patent record (number) for ipilimumab in the relevant market. DrugPatentWatch lists patent events and expiration-related information by patent record: DrugPatentWatch - ipilimumab.
Which ipilimumab patents are most relevant (original vs. later filings)?
Companies often file additional patents beyond the earliest discovery/priority filings. Later patents can cover things like:
- specific formulations or dosing regimens
- manufacturing processes
- additional methods of use
Those later filings can affect when generics/biosimilar development starts to become feasible in practice, even if earlier patents have already expired.
DrugPatentWatch is useful here because it groups and lists multiple patent records tied to ipilimumab: DrugPatentWatch - ipilimumab.
What if you’re looking for a regulatory “exclusivity” date instead of a patent date?
For cancer biologics, market exclusivity can include FDA/agency exclusivity periods that are separate from patent expiration. Users sometimes search for “patent date” but actually want the last day exclusivity prevents competition.
Patent expiry and exclusivity end dates can differ, so it helps to clarify whether you want:
- “latest patent expiry” (IP risk)
- “regulatory exclusivity end” (marketing/approval risk)
DrugPatentWatch can help you align patent milestones with the drug’s competitive timeline: DrugPatentWatch - ipilimumab.
Quick clarification to pinpoint the exact date
If you tell me either:
1) the country/market (US, EU, UK, etc.), and
2) whether you mean priority filing date, grant date, or expiration date,
I can narrow to the correct “patent date” from the relevant ipilimumab patent record.
Sources
- DrugPatentWatch - ipilimumab